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ABSTRACT
Aims To compare adolescent inhalant users without DSM-IV inhalant use disorders (IUDs) to youth with IUDs
(i.e. abuse or dependence) across demographic, psychosocial and clinical measures. Design Cross-sectional survey
with structured psychiatric interviews. Setting Facilities (n = 32) comprising the Missouri Division of Youth Services
(MDYS) residential treatment system for juvenile offenders. Participants Current MDYS residents (n = 723);
97.7% of residents participated. Most youth were male (87%) and in mid-adolescence (mean = 15.5 years,
standard deviation = 1.2, range = 11–20); more than one-third (38.6%, n = 279) reported life-time inhalant use.
Measurements Antisocial behavior, temperament, trauma-exposure, suicidality, psychiatric symptoms and
substance-related problems. Findings Among life-time inhalant users, 46.9% met criteria for a life-time DSM-IV IUD
(inhalant abuse = 18.6%, inhalant dependence = 28.3%). Bivariate analyses showed that, in comparison to non-users,
inhalant users with and without an IUD were more likely to be Caucasian, live in rural or small towns, have higher
levels of anxiety and depressive symptoms, evidence more impulsive and fearless temperaments and report more
past-year antisocial behavior and life-time suicidality, traumatic experiences and global substance use problems. A
monotonic relationship between inhalant use, abuse and dependence and adverse outcomes was observed, with
comparatively high rates of dysfunction observed among inhalant-dependent youth. Multivariate regression analyses
showed that inhalant users with and without an IUD had greater levels of suicidal ideation and substance use problems
than non-users. Conclusions Youth with IUDs have personal histories characterized by high levels of trauma, sui-
cidality, psychiatric distress, antisocial behavior and substance-related problems. A monotonic relationship between
inhalant use, abuse and dependence and serious adverse outcomes was observed.
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INTRODUCTION
Inhalant misuse is prevalent in the United States. Find-
ings from the 2006 Monitoring the Future nationally
representative survey of middle and high school youth
indicated that 16.1% of 8th graders had used inhalants
[1]. A somewhat lower life-time prevalence rate for inhal-
ant use was reported for 12–17-year-olds (10.1%) par-
ticipating in the National Survey on Drug Use and Health,
a household survey [2].
Contemporary studies of juvenile justice and sub-
stance abuse treatment-seeking samples, although few
in number, have documented high rates of inhalant use.
For example, Howard & Jenson [3] identified histories of
inhalant use in 34.4% of 475 juvenile probationers in the
state of Utah. More recently, Howard and colleagues [4]
determined that more than one-third of a state popula-
tion of adolescents remanded to treatment for antisocial
behavior had used inhalants. Howard & Jenson [3] and
Howard et al. [4] found significantly elevated rates of psy-
chiatric dysfunction, substance use problems and adverse
environmental circumstances in life-time inhalant users
compared to their non-inhalant-using peers.
Few studies have examined the abuse liability of
inhalants or population burden of DSM-IV IUDs (i.e.
inhalant abuse and dependence) among general or high-
risk populations. Howard & Perron [5] identified high
inhalant abuse liability for 279 adolescent inhalant users
with histories of antisocial behavior, such that approxi-
mately half of all youth initiating inhalant use eventually
met criteria for DSM-IV inhalant abuse or dependence.
Latent class findings in this study [5] suggested that
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inhalant abuse and dependence were distinct constructs.
Subsequent analyses appeared to demarcate effectively
inhalant use groups with lesser and greater levels of
problematic involvement with inhalants, as assessed by
responses to DSM-IV inhalant abuse and dependence cri-
teria. However, no direct comparisons of inhalant users
without IUDs to youth who had IUDs were performed and
youth with inhalant use, abuse and dependence were not
distinguished across a range of demographic and clini-
cally relevant psychosocial factors. High inhalant abuse
liability was also reported by Ridenour, Bray & Cottler [6];
however, other investigators have identified low inhalant
abuse liability in samples of adolescent [7] and adult [8]
inhalant users. Differences in sample composition, inhal-
ant use and IUD ascertainment and assessment protocols
and regional differences may account, in part, for these
discrepant findings.
Studies comparing adolescent inhalant users with
and without DSM-IV IUDs are largely absent from the
scientific literature. Sakai et al. [7] completed structured
diagnostic assessments with 847 adolescents drawn from
a substance abuse treatment program and found a sub-
stantial rate of life-time inhalant use (but low rates of
DSM-IV IUDs) and no significant differences between
inhalant users with and without IUDs with regard to
race, age, gender, prevalence of life-time DSM-IV sub-
stance use disorders, previous suicide attempt, conduct
disorder, history of physical abuse, sexual abuse, neglect,
abuse/neglect and major depression. In general, inhalant
users evidenced significantly more impairment across the
above-mentioned assessment domains than did inhalant
non-users.
In light of limited reports distinguishing adolescent
inhalant users with and without IUDs, we compared life-
time adolescent inhalant users without IUDs to youth
meeting life-time DSM-IV inhalant abuse or inhalant
dependence criteria across a range of socio-demographic,
psychiatric and substance use measures. Although, given
Sakai et al.’s [7] findings, it is possible that adolescent
inhalant users with and without IUDs do not differ sys-
tematically in clinically significant attributes (their most
salient characteristic perhaps being the decision to seek
intoxication via solvent inhalation that both groups
share and factors associated with this decision), we
hypothesized that a gradient of impairment would be
observed, such that inhalant-dependent youth would
exhibit greater dysfunction than youth who met only
inhalant abuse criteria who, in turn, would be more
impaired than youth with histories of inhalant use but no
IUDs. In this vein, D’Abbs & MacLean [9] noted that some
researchers regard intensive volatile solvent misuse as a
marker of ‘global vulnerability’ or as part of a ‘risk behav-
ior syndrome’ (p. xvii). If such is the case, we might
expect youth with greater levels of problematic involve-
ment with inhalants to differ significantly from their less
involved and non-involved counterparts across a wide
range of measures.
METHODS
Sampling frame and recruitment approach
Findings of the present study are based on a survey con-
ducted in 2003 of the population of current residents
across the 23 facilities of the Missouri Division of Youth
Services (MDYS) residential treatment system. The 723
adolescents who completed interviews constituted 97.7%
of MDYS residents at the time interviews were conducted.
MDYS youth are representative of delinquent youth in
state-mandated care nationally with regard to age,
gender and number of state youth in residential care per
100 000 adolescents, and represent the full continuum
of antisocial youth [9].
Sample description
Eighty-seven per cent of youth were male and approxi-
mately 40% reported that their family received public
assistance. Youth ranged from 11 to 20 years of age
[mean = 15.5, standard deviation (SD) = 1.2]; most lived
in small towns or cities (78.6, n = 569) as opposed to
suburban or rural areas (21.3%, n = 154). One-third
(n = 238) reported an African American identification,
7.7% (n = 56) a bi/multi-racial identification, 3.9%
(n = 28) a Latino/Latina identification and 55.4%
(n = 400) a Caucasian racial identification. Prevalently
used inhalants included gasoline (22%), permanent
markers (15%), computer ‘air duster’ (15%) and spray
paint (12%). One-third (38.6%; n = 279) of the sample
reported life-time inhalant use. Detailed descriptions of
this sample and their inhalant use have been reported
previously [4].
Participation in the study was voluntary. Data were
collected using structured interviews. Interviews were
conducted in large rooms at each facility that provided
private areas where confidential one-on-one interviews
were conducted. This study was approved by the MDYS
Institutional Review Board, Washington University
Human Studies Committee Institutional Review Board,
Federal Office of Human Research Protections, and was
granted a Certificate of Confidentiality by the National
Institute on Drug Abuse. Adolescents received $10.00 for
their participation.
Measurement
Participants were administered two assessments, the
Volatile Solvent Screening Inventory (VSSI) and the
Comprehensive Solvent Assessment Interview (CSAI). All
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participants completed the VSSI [4], which assesses
demographic characteristics, medical history, life-time
and past-year use of 55 volatile solvent inhalants, other
drug use and substance-related problems, current psychi-
atric symptoms and psychosocial problems. Consistent
with DSM-IV diagnostic guidelines, nitrite vasodilator
and nitrous oxide use were not considered inhalant use
for the purposes of this investigation.
Youth who reported life-time use of one or more vola-
tile solvents included in the VSSI also completed the CSAI
[4]. The CSAI includes an assessment of the settings,
modalities, peer and family networks, acute medical and
social consequences and other characteristics of adoles-
cent inhalant use. Items from the Diagnostic Interview
Schedule (DIS, version IV) were included to assess for the
presence of DSM-IV inhalant abuse and dependence dis-
orders. The DIS generally evidences good reliability for
assessment of substance use disorders [10]. IUD diagnoses
were assigned in accordance with DSM-IV guidelines.
Inhalant use and IUDs
Adolescent inhalant users were assigned a life-time inhal-
ant abuse diagnosis if they met one or more of four
DSM-IV criteria for inhalant abuse at some point in their
life-time and had never met criteria for DSM-IV inhalant
dependence. Inhalant users were assigned a life-time
inhalant dependence diagnosis if they had met three
or more of six DSM-IV inhalant dependence criteria
within a 12-month period at some point in their life-
times. A seventh generic DSM-IV substance dependence
criterion—withdrawal symptoms—was not included in
the inhalant dependence criteria set per specific DSM-IV
guidelines ([11] cf. p. 258). Youth who reported any use
of one or more volatile solvents for the purposes of intoxi-
cation [4] but who did not meet life-time criteria for inhal-
ant abuse or dependence were classified as inhalant users
without an IUD. Subjects with no reported history of
inhalant use were classified as inhalant non-users.
Substance use problems
Life-time substance-related problems were assessed with
the eight-item Alcohol/Drug Use Scale of the Massachu-
setts Adolescents Screening Instrument—2nd version
(MAYSI-2) developed for use with juvenile justice popula-
tions [12]. It should be noted that this measure assesses
substance use problems generically (i.e. not in relation to
specific substances of abuse) and therefore includes prob-
lems due to alcohol, inhalant and other psychoactive
drugs). The a coefficient in this study was 0.83.
Psychiatric symptom variables
Youth completed the Brief Symptom Inventory (BSI)
[13]. Two BSI subscales were included in this study:
depression and anxiety. Youth completed the five-item
MAYSI-2 suicide ideation scale. Grisso & Barnum [12]
reported a a reliability of 0.83 for this scale.
Trauma history
Adolescents also completed four items from the MAYSI-2
traumatic experiences scale, resulting in a scale range
of 0–4. Reliability in this study was a = 0.69.
Antisocial behavior and attitudes
The Self-Report of Delinquency (SRD) [14] was used to
assess the number of times in the year before they were
incarcerated youth engaged in delinquent behavior.
Study participants also completed the 56-item Psycho-
pathic Personality Inventory—short version (PPI-SV)
[15]. Two subscales of the PPI-SV employed in this analy-
sis were impulsive nonconformity and fearlessness.
Demographic and psychosocial variables
Gender, age, self-reported racial status, family receipt
of public assistance and geographical area of family
residence (i.e. urban/suburban, small town/rural) were
recorded for each youth.
Data analysis
Less than 1% of the total data points were missing, which
were imputed using the aregImpute function in the HMisc
package for R [16]. c2 tests and one-way analysis of vari-
ance (ANOVA) were used to compare differences between
inhalant user groups. Cramer’s V was used as an effect size
measure for associations based on c2 tests. R2 summarized
the effect size for associations for ANOVAs. Effect sizes were
interpreted using the general rules suggested by Cohen
[17]: ~0.10 was considered a small effect, ~0.30 a medium
effect and ~0.50 and greater a large effect. An effect size of
at least 0.20 was considered clinically significant [18].
Because R2 is a squared correlation, clinical significance
was based on the square of 0.20 (i.e. 0.04).
To help characterize the study sample, comparisons
were also made with normed data for MAYSI-2 and BSI
measures. For the MAYSI-2, the normed sample for com-
parison included committed youth in a secured facility
of the Massachusetts Department of Youth Services
(n = 582). For the BSI, the normed sample included
adolescents (n = 2408) from a non-clinical setting.
Logistic regression and multinomial logistic regres-
sions were used to identify factors discriminating inhalant
non-users, inhalant users without IUDs and inhalant
users with IUDs. Variables that were statistically signifi-
cant at the bivariate level were included in multivariate
analyses. To increase the interpretability of the odds ratios
for the primary multinomial regression model, a simula-
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tion analysis was conducted using the Zelig package for R
[19]. Additional simulation analyses for other models are
available from the first author upon request. The simula-
tion procedure gives probabilities for an outcome for the
variable of interest that can be easily interpreted.
RESULTS
Bivariate associations with inhalant use and
DSM-IV IUDs
Among life-time inhalant users, 46.9% met criteria for a
life-time DSM-IV IUD (inhalant abuse = 18.6%, inhalant
dependence = 28.3%). c2 tests indicated that gender, age,
and receipt of public assistance were not associated sig-
nificantly with inhalant use group membership (see
Table 1). However, adolescents who used inhalants or who
had IUDs were significantly more likely to identify as Cau-
casian and live in rural areas/small towns than non-
inhalant users. Inhalant-dependent youth had signifi-
cantly greater frequency of past-year delinquency than
did inhalant non-users, users or youth diagnosed with
inhalant abuse. Inhalant users and youth with IUDs had
significantly higher scores than inhalant non-users on
measures of impulsive non-conformity and fearlessness.
Inhalant users and youth with IUDs also exhibited greater
impairments than non-users on the MAYSI-2 measures of
suicidality, global substance use problems and trauma.
Inhalant-dependent youth had significantly higher
BSI anxiety and depression scale scores relative to other
groups of inhalant users and non-users. With respect to
severity of suicidal ideation, trauma exposure and sub-
stance use problems, graded relationships were observed.
Although differences were greatest between inhalant-
dependent youth and inhalant non-users, inhalant-
dependent youth also differed significantly from youth
with inhalant abuse on measures of anxious and de-
pressive symptoms, past-year delinquent conduct and
suicidal ideation.
Comparisons with normed data
Youth with a history of inhalant use, especially those
who met DSM-IV criteria for inhalant dependence, ex-
hibited higher scores on MAYSI-2 measures and BSI
measures than the normed samples. For example, on
measures of suicidality, life-time inhalant-dependent
youth had a mean score of 4.4, compared to 0.3 among
the normed sample. This trend was also similar on
measures of global substance use problems (mean = 6.5
versus 2.7), traumatic experiences (mean = 3.2 versus
2.5), depression (mean = 1.3 versus 0.8) and anxiety
(mean = 1.4 versus 0.8). Similar trends are also present
when comparing inhalant users without an IUD and
those with abuse to the normed sample (cf. Table 1).
Multinomial logistic regression analysis distinguishing
inhalant non-users, inhalant users without an IUD and
inhalant users with an IUD
In light of the significant bivariate differences observed
among the non-inhalant and inhalant user groups, a
multinomial logistic regression with simultaneous entry
of variables listed in Table 1 was conducted to identify
factors distinguishing inhalant users with and without
an IUD from inhalant non-users (the reference group).
The overall model exhibited a good fit with the data
(residual deviance = 985, log-likelihood = -492.8, df =
1424). Table 2 summarizes adjusted odds ratios (AOR)
and 95% confidence intervals (CI) for this model. This
model indicated that inhalant users without an IUD and
inhalant users with an IUD were significantly different
than non-users on measures of ethnicity, urbanicity,
impulsive non-conformity (inhalant users without IUDs
only), trait fearlessness, suicidal ideation and life-time
substance use problems.
Table 3 summarizes predicted probabilities (pp) of
class membership, derived from simulation procedures.
After holding all other values constant, the predicted
probabilities showed that white youth were almost twice
as likely as non-white youth to be inhalant users without
an IUD (pp = 0.24 versus 0.13) and with an IUD (0.08
versus 0.04). Fearlessness was also associated strongly
with inhalant use. Specifically, youth with high levels
of fearlessness were more than twice as likely have an
IUD compared to youth with low levels of fearlessness
(pp = 0.11 versus 0.05). This trend was also true with
respect to suicidal ideation (pp = 0.15 versus 0.05). Sub-
stance use problems were associated with a significantly
higher predicted probability of an IUD compared to low
substance use problems (pp = 0.39 versus 0.01).
Multinomial logistic regression analysis distinguishing
inhalant users, inhalant users with life-time inhalant
abuse and inhalant users with life-time inhalant
dependence
The first multinomial logistic regression model was
followed with an analysis intended to identify factors
distinguishing inhalant users without IUDs from those
with life-time abuse (without dependence) and life-time
dependence. The outcome variable was re-specified to
reflect these groups. All independent variables that
were significant at the bivariate level were included in
the model. The overall regression model exhibited a
good fit with the data (residual deviance = 449.7,
log-likelihood = -224.8, df = 536).
In comparison to inhalant users without an IUD,
youth with inhalant dependence had significantly higher
delinquency scores (AOR = 1.03, 95% = 1.01–1.05),
suicide ideation (AOR = 1.29, 95% CI = 1.10–1.51) and
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substance use problems (AOR = 1.74, 95% CI = 1.38–
2.19). Substance use problems discriminated inhalant
users without a disorder from youth with inhalant abuse
(AOR = 1.43, 95% CI = 1.17–1.75). No additional vari-
ables besides delinquency and substance use problems
were statistically significant.
Logistic regression analysis distinguishing inhalant
users with life-time abuse from users with life-time
dependence
A final multivariate model was specified to identify factors
distinguishing life-time inhalant abusers from life-time
Table 2 Multinomial regression comparing inhalant users with
(n = 148) and without (n = 131) an inhalant use disorder (IUD)
to inhalant non-users (n = 444).
Variable AOR 95% CI
Ethnicity, white (versus non-white)




Inhalant user 0.56 0.36–0.88
IUD 0.51 0.30–0.88
Impulsive non-conformity7–28
Inhalant user 1.06 1.01–1.12
IUD 1.01 0.94–1.08
Fearlessness7–28
Inhalant user 1.09 1.04–1.14
IUD 1.10 1.04–1.16
Total delinquency0–107
Inhalant user 0.99 0.98–1.01
IUD 1.01 0.99–1.02
BSI anxiety0–4
Inhalant user 0.92 0.63–1.33
IUD 1.38 0.89–2.14
BSI depression0–4
Inhalant user 1.14 0.80–1.62
IUD 0.84 0.55–1.29
MAYSI-2 suicide ideation0–6
Inhalant user 1.12 1.01–1.23
IUD 1.28 1.14–1.44
MAYSI-2 trauma0–4
Inhalant user 0.92 0.78–1.09
IUD 1.06 0.85–1.33
MAYSI-2 substance use problems0–8
Inhalant user 1.27 1.14–1.41
IUD 2.10 1.77–2.49
AOR: adjusted odds ratio; CI: confidence interval. Values in subscripts
represent the observed range of values for continuous variables. Inhalant
non-users were the reference group in all analyses. ‘Inhalant users’ were
youth with a life-time history of inhalant use who never met DSM-IV
criteria for an IUD. IUD refers to subjects who met life-time DSM-IV criteria
for inhalant abuse or dependence. All values in bold type are statistically
significant based on a 95% CI that does not bound 1.0. BSI: Brief
Symptom Inventory; MAYSI-2: Massachusetts Youth Screening Instru-
ment, version 2.
Table 3 Predicted probability of inhalant user type class
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CI: confidence interval. Predicted probabilities were computed by taking
random draws from the posterior distribution of the multinomial logistic
regression model. All predicted probabilities were adjusted for ethnicity,
urbanicity, impulsive non-conformity, fearlessness, total delinquency in
prior 12 months, Brief Symptom Inventory (BSI) anxiety, BSI depression,
Massachusetts Youth Screening Instrument, version 2 (MAYSI-2) suicide
ideation, MAYSI-2 trauma, and MAYSI-2 substance use problems; adjust-
ments excluded the variable that was modeled.
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inhalant dependants. Again, all variables significant at
the bivariate level were included in the model. The overall
model exhibited a good fit (residual deviance = 149.0,
log-likelihood = -74.49, df = 120). Two variables distin-
guished inhalant abusers from inhalant dependants:
youth with inhalant dependence had significantly higher
scores on measures of delinquency (AOR = 1.74, 95%
CI = 1.38–2.19), and suicide ideation (AOR = 1.23, 95%
CI = 1.03–1.47) than youth diagnosed with only inhal-
ant abuse.
DISCUSSION
Prior studies have documented functional impairments,
including high rates of substance use and psychiatric
disorders, in life-time inhalant users compared to inhal-
ant non-users in the general population [20,21] and
various subpopulations [3,4] of adolescents. However,
only one previous investigation, to our knowledge,
examined impairments across a gradient of problematic
inhalant use involvement. Unlike Sakai et al. [7], we
found some evidence of a monotonic relationship
between severity of inhalant use problems, as reflected
in formal DSM-IV diagnoses of inhalant abuse and
dependence and indices of psychiatric symptoms, sub-
stance abuse, antisociality and other dysfunctions. It is
notable that Sakai et al. [7] reported differences between
inhalant users with and without IUDs for prevalence
of life-time DSM-IV major depression (39% versus 23%),
prior suicide attempt (32% versus 27%), life-time
conduct disorder (96% versus 93%), alcohol use disorder
(93% versus 83%), nicotine dependence (79% versus
73%) and amphetamine use disorders (36% versus
27%). Although these values did not show statistically
significant differences, they were consistent in direction
with the findings of this report. Perhaps the use of con-
tinuous measures of depression, sucidality and other
variables permitted a more sensitive test of differences
between inhalant use groups in the current study than
the categorical variables employed by Sakai et al. [7]. The
life-time prevalence of inhalant use in the Sakai et al.
sample (i.e. 18%) was approximately half that observed
in this study and the proportion of youth progressing
from inhalant initiation to IUDs was much lower in the
Sakai et al. study than in the current investigation. It
is probable, therefore, that the statistical power to detect
differences between inhalant use groups was not as
high in the Sakai et al. investigation as in the current
study, given the much lower rates of IUDs in the former
study. In any case, it is notable that significant differ-
ences between inhalant use groups were identified in
the current study, given that youth were sampled from
a population with presumably restricted range across a
number of assessed variables.
The reported levels of IUD identified in this sample,
although significantly higher than those reported in most
prior studies of adolescent inhalant users, are not entirely
unprecedented. Ridenour et al. [6] recently studied
the prevalence of DSM-IV IUDs in a sample of 162
community-residing inhalant users living in St Louis. A
total of 40.2% (27.9% abuse; 12.3% dependence) of
inhalant users (average age = 20.3, SD = 2.4) met crite-
ria for IUDs. It is unclear whether the high abuse liability
of inhalants reported by Ridenour et al. [6] and in the
current study reflects prevalent use of inhalants in the
Missouri state region of the United States, or regional
differences in the pattern of inhalant use or products used
which favor development of inhalant abuse and depen-
dence. It is important to recognize that inhalant users in
the current study were identified using a comprehensive
instrument. It is also possible that the delinquent client
population studied in this report was significantly
enriched for inhalant use.
Our finding that IUDs were correlated commonly with
measures of substance use problems, psychiatric symp-
toms and antisocial characteristics is consistent with
d’Abbs & MacLean’s [9] reference to volatile solvent
misuse as an indicative of a ‘risk behavior syndrome’ or
‘global vulnerability marker’ (p. xvii). Thus, it is likely that
clinicians encountering youth with IUDs will, in practice,
be working with youth with multiple disorders requir-
ing extensive intervention and rehabilitation. Further,
our findings suggest that as the severity of inhalant-
related problems increases, so too will the severity of
co-occurring psychiatric and substance-related condi-
tions. Thus, social and health authorities, particularly
those charged with working with youth in the juvenile
justice system, should consider screening routinely for
IUDs using an extensive (although brief to administer)
screen for inhalant use and IUDs.
Although the finding of graded differences between
inhalant users, abusers and dependants with regard
to psychosocial characteristics and various functional
impairments is noteworthy, our results should be inter-
preted cautiously. We relied on youths’ self-reports
of unverified validity and the antisocial nature of the
sample may itself limit the generalizabilty of reported
findings. However, antisocial youth are an important
client population in their own regard. The use of struc-
tured psychiatric interviews, high rate of youth partici-
pation, understudied youth population and infrequently
investigated psychoactive agents are key strengths of
this research. This study also builds on the strengths
of existing work by maintaining consistency with
DSM-IV diagnostic guidelines, such that nitrite vasodi-
lator and nitrous oxide were not included as inhalant
use. Further, the population of youth we studied was
heterogeneous with regard to prior antisocial behavior
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